Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Biopharmaceutics & Drug Disposition|September 24, 2004
A multiple-dose, safety, tolerability, pharmacokinetics and pharmacodynamic study of oral recombinant human interleukin-11 (oprelvekin)Monette M Cotreau, Lucille Stonis, Andrew Strahs, et al.Clinical Pharmacokinetics|January 7, 2005
The influence of age and sex on the clearance of cytochrome P450 3A substratesMonette M Cotreau, Lisa L von Moltke, David J GreenblattClinical Pharmacology in Drug Development|April 30, 2016
Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitorMonette M Cotreau, Nicholas M Siebers, James Miller, et al.Clinical Pharmacology in Drug Development|April 30, 2016
The effect of food on the pharmacokinetics of tivozanib hydrochlorideMonette M Cotreau, Lisa Massmanian, Andrew L Strahs, et al.Clinical Pharmacology in Drug Development|April 30, 2016
A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumorsKathleen Moore, Jeffrey R Infante, Monette M Cotreau, et al.Journal of Clinical Pharmacology|February 8, 2002
Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal womenMonette M Cotreau, Lucille Stonis, Kevin H Dykstra, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance StudyMonette M Cotreau, Christine L Hale, Lindsey Jacobson, et al.Journal of Clinical Pharmacology|October 1, 2003
The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humansMonette M Cotreau, Sarah Warren, John L Ryan, et al.Journal of Clinical Pharmacology|May 20, 2005
A single administration of recombinant human interleukin-12 is associated with increased expression levels of interferon-gamma and signal transducer and activator of transcription in healthy subjectsCaroline Trudeau, Monette M Cotreau, Lucille Stonis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumorsFerry A L M Eskens, Maja J A de Jonge, Pankaj Bhargava, et al.Pageof 2